Other novel therapies based on specific leukemia biology, such as CBP/catenin inhibitor (ICG-001) (148), interleukin 27 administration (149), spleen-tyrosine kinase (SYK) inhibitors (150), anti-connective tissue growth factor (CTGF) monoclonal antibody (151) for pre-B ALL, and anti-Notch1 monoclonal antibodies or for T ALL (152), were all shown to prolong survival and/or reduce engraftment in NOD-SCID or NSG mice, with or without additional chemotherapy. Here, SYK is linked to acute lymphoblastic leukemia.